Inactive Instrument

News Aevi Genomic Medicine Inc Nasdaq

Equities

US58436Q2030

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2020	Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index	CI
2020	Aevi Genomic Medicine, Inc. Announces Resignation of Directors	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index	04/20/04	CI
AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	04/20/04	AQ
Aevi Genomic Medicine, Inc. Announces Resignation of Directors	04/20/04	CI
Aevi Genomic Medicine, LLC(NasdaqCM:GNMX) dropped from NASDAQ Composite Index	03/20/03	CI
Cerecor Inc. completed the acquisition of Aevi Genomic Medicine, Inc..	03/20/03	CI
AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)	23/19/23	AQ
AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)	11/19/11	AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	10/19/10	AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	06/19/06	AQ
Aevi Genomic Medicine, Inc. Doses the First Patient with AEVI-002 in A Phase Ib Clinical Trial	23/19/23	CI
AEVI GENOMIC MEDICINE, INC. : Other Events (form 8-K)	23/19/23	AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K)	21/19/21	AQ
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/19/14	CI
Cerecor Inc. entered into a definitive merger agreement to acquire Aevi Genomic Medicine, Inc. for $15.6 million.	14/19/14	CI
Aevi Genomic Medicine, Inc. : Receives Positive Nasdaq Listing Determination	15/19/15	PR
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/19/14	CI
Aevi Genomic Medicine : Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody	07/19/07	PR
Aevi Genomic Medicine, Inc. Obtains License for Medi2338, Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18)	07/19/07	CI
Aevi Genomic Medicine : to Present at the 2019 Wedbush PacGrow Healthcare Conference	06/19/06	PR
Aevi Genomic Medicine : Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor	16/19/16	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aevi Genomic Medicine Inc Nasdaq

Equities

US58436Q2030

Summary

Filters